These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 25306975)
1. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Abraham J Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975 [TBL] [Abstract][Full Text] [Related]
2. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]
3. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Slomovitz BM; Coleman RL Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003 [TBL] [Abstract][Full Text] [Related]
4. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Grunt TW; Mariani GL Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720 [TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779 [TBL] [Abstract][Full Text] [Related]
6. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. O'Regan R; Hawk NN Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875 [TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers? Zardavas D; Fumagalli D; Loi S Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556 [TBL] [Abstract][Full Text] [Related]
9. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Dey N; De P; Leyland-Jones B Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025 [TBL] [Abstract][Full Text] [Related]
10. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Ghayad SE; Cohen PA Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211 [TBL] [Abstract][Full Text] [Related]
12. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Mabuchi S; Kuroda H; Takahashi R; Sasano T Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064 [TBL] [Abstract][Full Text] [Related]
13. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Polivka J; Janku F Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502 [TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Zhou Q; Lui VW; Yeo W Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Maira SM; Furet P; Stauffer F Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073 [TBL] [Abstract][Full Text] [Related]
16. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
17. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. McKenna M; McGarrigle S; Pidgeon GP Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):185-197. PubMed ID: 30318472 [TBL] [Abstract][Full Text] [Related]
18. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Fumarola C; Bonelli MA; Petronini PG; Alfieri RR Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259 [TBL] [Abstract][Full Text] [Related]
19. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Burris HA Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372 [TBL] [Abstract][Full Text] [Related]
20. [Antihormonal therapy in breast cancer and mTOR inhibitors]. Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]